Form 4: Lyell Immunopharma COO Stephen Hill Reports Stock and Option Awards

Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, reports the acquisition of stock and option awards.

Summary

• Stephen J. Hill, the Chief Operating Officer of Lyell Immunopharma, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On February 10, 2025, Hill acquired 112,500 shares of common stock at $0 and was granted options to purchase 506,250 shares of common stock at an exercise price of $0.5535.
• Following these transactions, Hill directly owns 172,899 shares of common stock and options to purchase 506,250 shares.
• The stock and option awards are subject to vesting schedules, with portions vesting on August 9, 2025, and subsequently over time, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.

Positives

• The grant of stock and option awards to the COO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.
• The performance-based options further incentivize the achievement of specific performance criteria.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules suggest an expectation of continued service and contribution from the COO.

Industry Context

Stock and option awards are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. The vesting schedules are designed to align management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used by companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedules described are typical, with initial vesting occurring around one year after the grant date, followed by monthly or quarterly vesting over several years.
• The exercise price of $0.5535 is relatively low, which is not unusual for early-stage biotech companies.

Stakeholder Impact

• Shareholders may view the stock and option awards positively, as they align the COO's interests with the company's long-term success.
• Employees may be motivated by the fact that key executives are incentivized to drive company performance.
• The awards do not have a direct impact on customers, suppliers, or creditors.

Key Dates